The stock of Fluidigm Corporation (NASDAQ:FLDM) is a huge mover today! The stock decreased 4.76% or $0.4 during the last trading session, hitting $8.01. About 194,140 shares traded hands or 45.57% up from the average. Fluidigm Corporation (NASDAQ:FLDM) has risen 26.66% since February 26, 2016 and is uptrending. It has outperformed by 16.23% the S&P500.
The move comes after 6 months negative chart setup for the $227.97M company. It was reported on Oct, 1 by Barchart.com. We have $6.97 PT which if reached, will make NASDAQ:FLDM worth $29.64M less.
Analysts await Fluidigm Corporation (NASDAQ:FLDM) to report earnings on November, 3. They expect $-0.54 earnings per share, down 80.00% or $0.24 from last year’s $-0.3 per share. After $-0.47 actual earnings per share reported by Fluidigm Corporation for the previous quarter, Wall Street now forecasts 14.89% negative EPS growth.
Fluidigm Corporation (NASDAQ:FLDM) Ratings Coverage
Out of 5 analysts covering Fluidigm (NASDAQ:FLDM), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Fluidigm has been the topic of 17 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The stock of Fluidigm Corporation (NASDAQ:FLDM) has “Hold” rating given on Wednesday, August 26 by Cantor Fitzgerald. The rating was upgraded by Zacks to “Sell” on Friday, August 21. The stock has “Buy” rating given by Cantor Fitzgerald on Friday, October 30. Mizuho maintained Fluidigm Corporation (NASDAQ:FLDM) on Friday, August 5 with “Buy” rating. The stock of Fluidigm Corporation (NASDAQ:FLDM) earned “Buy” rating by Mizuho on Friday, February 5. Mizuho maintained Fluidigm Corporation (NASDAQ:FLDM) on Sunday, August 9 with “Hold” rating. The rating was downgraded by Piper Jaffray to “Neutral” on Friday, August 7. The stock of Fluidigm Corporation (NASDAQ:FLDM) earned “Hold” rating by Maxim Group on Thursday, August 27. The stock of Fluidigm Corporation (NASDAQ:FLDM) earned “Neutral” rating by Mizuho on Friday, October 30. The rating was initiated by Deutsche Bank on Thursday, January 7 with “Buy”.
According to Zacks Investment Research, “Fluidigm Corporation operates as a biotech tools company that creates microfluidic-based chips and instrumentation for biological research. Products offered by the Company include BioMark HD System- a real time PCR; EP1 system for SNP genotyping; Access Array System-an Integrated Fluidic Circuit (IFC); TOPAZ system for protein crystallography; Dynamic Array integrated fluidic circuits (IFCs); and Access Array Assay Design Services. The Company’s products find its application in Gene Expression, Single-Cell Gene Expression, SNP Genotyping, Targeted Resequencing, Sample Quantitation, Copy Number Variation and Protein Crystallization. Fluidigm Corporation is based in San Francisco, California.”
Insitutional Activity: The institutional sentiment decreased to 0.82 in Q2 2016. Its down 0.14, from 0.96 in 2016Q1. The ratio dived, as 14 funds sold all Fluidigm Corporation shares owned while 31 reduced positions. 8 funds bought stakes while 29 increased positions. They now own 25.56 million shares or 9.86% less from 28.35 million shares in 2016Q1.
Blackrock Invest Lc reported 109,868 shares or 0% of all its holdings. Moreover, Parametric Ltd has 0% invested in Fluidigm Corporation (NASDAQ:FLDM) for 21,070 shares. Vanguard Gp has 1.08M shares for 0% of their US portfolio. Sei Invests Communication has 0% invested in the company for 3,334 shares. Neuberger Berman Grp Limited Liability Company owns 926,340 shares or 0.01% of their US portfolio. Wellington Management Grp Inc Ltd Liability Partnership holds 0% or 652,516 shares in its portfolio. Legal And General Grp Plc, a United Kingdom-based fund reported 4,371 shares. Stoneridge Investment Partners Lc reported 24,396 shares or 0.03% of all its holdings. Keybank Natl Association Oh holds 0% of its portfolio in Fluidigm Corporation (NASDAQ:FLDM) for 16,927 shares. Thompson accumulated 0.03% or 16,200 shares. Walleye Trading has 1,368 shares for 0% of their US portfolio. Manufacturers Life Insurance The accumulated 22,238 shares or 0% of the stock. Columbia Wanger Asset Ltd Llc holds 0.19% of its portfolio in Fluidigm Corporation (NASDAQ:FLDM) for 1.78 million shares. Qs Invsts Ltd Limited Liability Company has 29 shares for 0% of their US portfolio. State Street accumulated 456,045 shares or 0% of the stock.
More notable recent Fluidigm Corporation (NASDAQ:FLDM) news were published by: Quotes.Wsj.com which released: “Fluidigm Corp. FLDM (US: Nasdaq)” on February 11, 2011, also Fool.com with their article: “Why Fluidigm Corporation is Soaring Higher” published on October 30, 2015, Fool.com published: “Why Shares in Fluidigm Corporation Are Bursting” on May 08, 2015. More interesting news about Fluidigm Corporation (NASDAQ:FLDM) were released by: Globenewswire.com and their article: “Fluidigm Appoints New President and Chief Operating Officer” published on August 04, 2016 as well as Thestreet.com‘s news article titled: “Fluidigm (FLDM) Stock Plummeting After Earnings Results” with publication date: August 07, 2015.
FLDM Company Profile
Fluidigm Corporation, incorporated on March 29, 2007, creates, makes and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Firm sells instruments and consumables, including integrated fluidic circuits, assays and reagents, to academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology (Ag-Bio) companies. The Firm operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. The Firm offers various types of products, which include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.